TY - JOUR ID - 10732 TI - Clinical outcomes of ultrathin strut biodegradable polymer-coated everolimus-eluting stent in patients with coronary artery disease JO - ARYA Atherosclerosis Journal JA - ARYA LA - en SN - 1735-3955 AU - Patted, Suresh V. AU - Thakkar, Ashok S. AD - Professor, Department of Cardiology, KLE Academy of Higher Education & Research, Belagavi, Karnataka, India AD - Head, Department of Clinical Research, Meril Life Sciences Pvt. Ltd., Vapi, Gujarat, India Y1 - 2020 PY - 2020 VL - 16 IS - 3 SP - 130 EP - 135 KW - Coronary Artery Disease KW - Drug-Eluting Stent KW - Everolimus KW - Percutaneous Coronary Intervention DO - 10.22122/arya.v16i3.1827 N2 - BACKGROUND: Evermine 50™ (Meril Life Sciences Pvt. Ltd., India) everolimus-eluting stent system (EES) is a novel ultrathin strut (50 µm) cobalt-chromium coronary drug-eluting stent (DES) platform with biodegradable polymer coating. The Evermine 50 EES-KLES study aimed to evaluate the Evermine 50 EES in terms of 24-month clinical safety and performance in patients with coronary artery disease (CAD).METHODS: This retrospective study consisted of 171 patients (258 lesions) implanted with Evermine 50 EES for managing CAD. We analyzed the major adverse cardiac events (MACE) incidence, defined as a composite of cardiac death, myocardial infarction, and ischemia-driven target lesion revascularization (ID-TLR) at 6-, 12-, and 24-month follow-up.RESULTS: A total of 171 patients were included with a mean age of 57.85 ± 10.05 years, of which, 139 (81.29%) were men, 69 (40.35%) were hypertensive, and 70 (40.94%) were diabetic. The incidence of MACE was 1 (0.58%), 3 (1.81%), and 4 (2.42%) at 6-, 12-, and 24-month follow-up, respectively. There were three cases (1.82%) of cardiac death and one case (0.61%) of ID-TLR up to 24 months. None of the patients was presented with definite or probable stent thrombosis (ST).CONCLUSION: This study demonstrated that implantation of ultrathin strut Evermine 50 EES resulted in a low rate of incidence of MACE, indicating a favourable clinical safety and performance profile of Evermine 50 EES in patients with CAD [Clinical Trials Registry-India (CTRI) Number: CTRI/2017/09/009939)]. UR - https://arya.mui.ac.ir/article_10732.html L1 - https://arya.mui.ac.ir/article_10732_860fa63a6d001cef63daf081a3d0df98.pdf ER -